NEW YORK – Molecular testing developer ABL Diagnostics said on Monday that it has signed an exclusive distribution deal with Tokyo-based Riken Genesis to promote and commercialize its infectious disease tests in Japan. Financial terms of the agreement were not disclosed.

纽约——分子检测开发商ABL诊断公司周一表示，已与东京的Riken Genesis签署了一项独家分销协议，以在日本推广和商业化其传染病检测产品。该协议的财务条款尚未披露。

ABL Diagnostics' parent company, Advanced Biological Laboratories, recently

ABL诊断公司的母公司，高级生物实验室，最近

acquired

获得

the rights to a portfolio of PCR tests from Siemens Healthineers'

西门子医疗的一组PCR测试组合的权利

shuttered

关闭的

Fast Track Diagnostics business.

快速诊断业务。

Under the distribution deal with Woippy, France-based ABL Diagnostics, Riken Genesis will offer the UltraGene qPCR assays and syndromic panels made by Advanced Biological Laboratories.

根据与法国沃伊普ABL诊断公司的分销协议，Riken Genesis将提供由高级生物实验室制造的UltraGene qPCR检测和综合征面板。

The agreement also covers ABL Diagnostics' DeepChek genotyping PCR assays and analysis software, validated for use with Sanger and next-generation sequencing workflows.

该协议还涵盖了ABL诊断公司的DeepChek基因分型PCR检测和分析软件，这些产品已验证可与桑格测序和下一代测序工作流程一起使用。

In a statement, Riken Genesis president and CEO Kenji Iwakabe noted that his firm was a former distributor in Japan of the products related to the Fast Track Diagnostics IP acquired by ABL.

理研创世总裁兼首席执行官岩壁健治在一份声明中指出，他的公司曾是ABL收购的Fast Track Diagnostics知识产权相关产品在日本的经销商。

'We believe this new partnership with ABL Diagnostics will enable us to continue providing our customers with robust qPCR solutions that have a proven track record in Japan, while also incorporating advanced sequencing-based genotyping technologies for microbiology,' Iwakabe said.

“我们相信，与ABL诊断公司的这一新合作伙伴关系将使我们能够继续为客户提供在日本有成功记录的强大qPCR解决方案，同时还将整合基于先进测序的微生物基因分型技术，”岩壁说。

ABL Diagnostics' growing portfolio includes HIV diagnostics and drug resistance assays, including a whole-genome sequencing kit, genotyping and drug resistance tests for SARS-CoV-2, tuberculosis, hepatitis B and C, bacterial 16S/18S RNA-based microbiome and taxonomy analyses, as well as molecular tests for other bacterial and viral targets.

ABL诊断公司不断增长的产品组合包括HIV诊断和耐药性检测，包括全基因组测序试剂盒、SARS-CoV-2、结核病、乙型和丙型肝炎的基因分型和耐药性测试、基于细菌16S/18S RNA的微生物组和分类学分析，以及其他细菌和病毒目标的分子检测。

In addition, the firm offers syndromic qPCR tests and the Nadis electronic medical record (EMR) system that is used in more than 200 hospitals in France for HIV and hepatitis patient management. .

此外，该公司还提供综合征qPCR检测和Nadis电子病历（EMR）系统，该系统在法国200多家医院用于艾滋病和肝炎患者的管理。